GlassScriptPhysician profile
Suzanne Seeley
NPI 1871116285
$3,343.04
in general payments reported to CMS, 2019-2025
23 companies · $654 in 2025
The $654 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $537 · 2023: $1,520 · 2024: $632 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,379 · Travel and Lodging: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,379.14 |
| Travel and Lodging | $426.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $927.27 | 2023-2024 | Watchman Access System, Watchman Flx |
| Abbvie INC. | $592.91 | 2022-2025 | |
| Novo Nordisk INC | $346.93 | 2022-2024 | Ozempic, Rybelsus, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $261.38 | 2024-2025 | Lifevest |
| Amgen INC. | $177.17 | 2022-2025 | Repatha, Repatha |
| Cvrx, INC. | $161.73 | 2025 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.38 | 2022-2025 | Jardiance |
| Pfizer INC. | $154.76 | 2022-2024 | |
| Cumberland Pharmaceuticals, INC. | $65.07 | 2023 | Kristalose |
| Idorsia Pharmaceuticals US INC | $58.76 | 2022-2023 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $58.01 | 2023-2024 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $53.72 | 2022-2023 | Xifaxan |
| Bausch Health US, LLC | $43.92 | 2022-2024 | Aplenzin, Wellbutrin |
| Glaxosmithkline, LLC. | $43.63 | 2022-2023 | Trelegy Ellipta |
| Lilly USA, LLC | $43.48 | 2022-2024 | Mounjaro, Jardiance, Zepbound |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $38.83 | 2025 | |
| Neos Therapeutics, LP | $31.45 | 2023 | Adzenys Xr-Odt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.42 | 2023 | |
| Amarin Pharma, INC. | $27.63 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.81 | 2023 | Gvoke Hypopen |
| Vivus LLC | $16.18 | 2023 | Qsymia |
| Sanofi-Aventis U.S. LLC | $14.93 | 2022 | |
| Currax Pharmaceuticals LLC | $14.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Seeley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.